Table 3

Countries productive of schizophrenia trials ordered by level of productivity

country

GDP (mUS $)

actual trials > 100

predicted trials

% predicted output (95% confidence intervals)


Finland

119834

38

2

1900 (1312–2488)

South Africa

129094

26

5

520 (340–700)

Denmark

161455

79

12

658 (525–792)

Canada

607702

275

118

233 (212–254)

Norway

153362

24

10

240 (167–313)

Greece

118172

15

2

750 (397–1103)

Switzerland

172400

54

15

360 (278–442)

Sweden

227757

101

28

361 (301–421)

Poland

135623

17

6

283 (175–392)

UK

1283335

669

279

240(226–254)

Netherlands

363342

104

60

173(152–196)

Belgium

242508

49

32

153 (128–178)

Austria

206236

33

23

143 (117–170)

USA

7824008

2363

1831

129 (127–132)

Hong Kong

175200

18

16

113 (95–130)

Australia

402787

64

70

91 (85–98)

India

388649

48

66

73 (60–85)

Germany

2089845

256

470

54 (48–61)

Nigeria

142920

4

8

50 (1–99)

China

901981

87

188

46 (36–57)

Turkey

191865

8

19

42 (8–76)

Thailand

153909

4

10

40 (-8–88)

Italy

1145370

91

246

37 (27–47

France

1394124

108

305

35 (26–44)

Spain

531289

32

100

32 (16–48)

Russian Federation

447103

21

80

26 (7–45)

Mexico

402109

13

69

19 (-2–40)

Iran

159391

2

12

17 (-35–68)

Saudi Arabia

134825

1

6

17 (-56–90)

Republic of Korea

442543

13

79

16 (-4–37)

Brazil

806972

21

166

13 (-2–27)

Argentina

323548

6

51

12 (-14–38)

Japan

4192669

113

969

12 (6–18)

Taiwan

308000

4

47

9 (-19–36)


Moll et al. BMC Psychiatry 2003 3:18   doi:10.1186/1471-244X-3-18

Open Data